Related Experiment Videos
Clinical experience with gefitinib: an update
Federico Cappuzzo1, Giovanna Finocchiaro, Giulio Metro
1Bellaria Hospital, Department of Medical Oncology, Bologna, Italy. federico.cappuzzo@ausl.bo.it
Critical Reviews in Oncology/Hematology
|March 15, 2006
Summary
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows promise in non-small cell lung cancer (NSCLC). Patient selection based on EGFR mutations may improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gefitinib is a targeted therapy inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TKI).
- It has shown activity in non-small cell lung cancer (NSCLC), improving symptoms and quality of life.
- Previous trials with unselected patients yielded variable response rates (9-19%).
Purpose of the Study:
- To review clinical trial results of gefitinib in NSCLC and other solid tumors.
- To explore biological mechanisms of EGFR-TKI sensitivity.
- To identify predictive biomarkers for gefitinib efficacy.
Main Methods:
- Review of published clinical trials involving gefitinib.
- Analysis of biological data on EGFR mutations and signaling pathways.
- Correlation of clinical outcomes with molecular markers.
Main Results:
- Gefitinib demonstrated responses in heavily pretreated NSCLC patients.
- EGFR gene mutations and amplification are linked to increased sensitivity.
- Tumors with activated Akt signaling may also predict response.
- Lack of patient selection in prior phase III trials may explain negative results.
Conclusions:
- Gefitinib is an effective EGFR-TKI for NSCLC.
- Specific EGFR mutations and pathway activations are key predictors of gefitinib sensitivity.
- Future trials should incorporate patient selection based on these biomarkers for improved outcomes.